What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 5 months ago
Placebo Works Best in Combination
Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background MTX.
https://t.co/JmNGRQWv6L https://t.co/77LdcTwCvl
Dr. John Cush RheumNow
3 years 5 months ago
New Updated GRAPPA Psoriatic Arthritis Recommendations
The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains."
https://t.co/PkDofio1eh https://t.co/kp6UEgwonV
Dr. John Cush RheumNow
3 years 5 months ago
Video: Post Hoc Analysis of the ORAL Surveillance Study
https://t.co/PVzfYlzdQa https://t.co/0RpA3CfTEE
Dr. John Cush RheumNow
3 years 5 months ago
Gabapentin Implicated in Overdose Deaths
Recent FDA and MMWR warnings suggest that gabapentin was present in almost 10% of US overdose deaths between 2019 & 2020. The report also stated that gabapentin was the cause of the death in half of these cases.
https://t.co/ilNAd7ifdZ https://t.co/5GIcySXSDZ
Dr. John Cush RheumNow
3 years 5 months ago
No science to F/U visit scheduling. Study of 114 outpt SpA visits, 34% considered unnecessary (fewer Rx change 15 v 52%) & clinical actions (23 v 63%) visits) vs. "necessary" visits (predict by ASDAS ≥2.1 & PtGA ≥3 >80%). Remote monitoring role? https://t.co/J8TIQRb0LG https://t.co/TCSN0NaeC8
Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com. Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.
Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background methotrexate (MTX).
Dr. John Cush RheumNow
3 years 5 months ago
Video: Cancer after Biologic Use in Patients with a History of Prior Malignancy
https://t.co/jr37Ti7c9J https://t.co/iYCXzhXD44
Dr. John Cush RheumNow
3 years 5 months ago
Study of contoured foot orthoses vs sham shoe insoles in 1st MTP #OA pain: 87 pts completed 12 wk trial that showed no differences in 1st MTP walking pain or other 2nd outcomes. Hard orthoses are no more effective than flat sham insoles https://t.co/XAFWwpSjHm https://t.co/g5J9TbG2pQ
Dr. John Cush RheumNow
3 years 5 months ago
Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/YqfOu0X3jY https://t.co/fPBzogQFal
Dr. John Cush RheumNow
3 years 5 months ago
Full read review of Inclusion body myositis: an untreatable, slowly progressive muscle disorder seen w/ aging; distinctive pattern of weakness involving the quadriceps and finger flexor muscles, w/ certain genetic predispositions https://t.co/BxwyTacnZF https://t.co/c4wDkX6Yi9
Dr. John Cush RheumNow
3 years 5 months ago
Danish IBD+RA registry study of TNFi induced Psoriasis in 109k non-PSO pts (20K on TNFi). PSO risk equal betw non-TNFi & conventional Rx. Compared to latter, TNFi increased nonpustular PSO (HR 2.12; NNH 342 PY) & pustular PSO (HR 6.5; NNH 909 PY) https://t.co/5l3qlyYoFy https://t.co/Ce4RmnfHOm
Poster Hall